Aligos Therapeutics stock jumps on $25M China licensing deal

Aligos Therapeutics stock has surged following the announcement of a licensing agreement in China. The deal is valued at $25 million, triggering a positive market reaction and a jump in the company's share price. Investors are responding to this strategic move as the company expands its reach through this specific financial arrangement. The stock's upward momentum is directly linked to the news of this multi-million dollar partnership within the Chinese market for their therapeutic developments.